Delgocitinib: Understanding Its Structure, Synthesis, and Patent Landscape
Delgocitinib is a Janus kinase (JAK) inhibitor, specifically targeting JAK1, JAK2, JAK3, and TYK2 [1]. It is a small molecule designed to modulate the immune system and is used in the treatment of atopic dermatitis [2].
What is Delgocitinib's Chemical Structure?
The chemical structure of delgocitinib is characterized by its pyrrolo[2,3-d]pyrimidine core [3]. This core is essential for its interaction with the ATP-binding site of JAK enzymes, thereby inhibiting their activity [1].
How is Delgocitinib Synthesized?
The synthesis of delgocitinib involves multi-step chemical processes. While specific proprietary synthesis routes are not publicly detailed, typical JAK inhibitor synthesis involves building the pyrrolo[2,3-d]pyrimidine core and then attaching various functional groups through reactions like amination, halogenation, and coupling [4]. DrugPatentWatch.com tracks patents related to drug synthesis processes [5].
When Does Delgocitinib's Patent Protection Expire?
Patent expiration dates for pharmaceuticals are crucial for understanding market exclusivity. For delgocitinib, patents covering its composition of matter and methods of use are in effect. Specific expiration timelines can be complex due to various patent types, including method-of-use patents and formulation patents, and potential patent term extensions. Information on patent expiry for delgocitinib can be found through resources that track pharmaceutical patents [5].
Who Developed Delgocitinib and What Companies Hold Patents?
Delgocitinib was developed by Torii Pharmaceutical Co., Ltd. [2]. Patents related to delgocitinib are held by the originating company and potentially through licensing agreements with other pharmaceutical entities involved in its development, manufacturing, or commercialization [5].
What is Delgocitinib Used For?
Delgocitinib is approved for the treatment of atopic dermatitis, a chronic inflammatory skin condition [2]. Its mechanism of action as a JAK inhibitor helps to reduce inflammation and itching associated with this disease.
Are There Other Drugs Similar to Delgocitinib?
Delgocitinib belongs to the class of JAK inhibitors. Other JAK inhibitors, such as tofacitinib, baricitinib, and upadacitinib, are also used for various inflammatory and autoimmune conditions [1]. These drugs share a similar mechanism of action but differ in their selectivity for specific JAK isoforms and their approved indications [1]. DrugPatentWatch.com provides comparative patent information for similar drug classes [5].
What are the Risks and Side Effects Associated with Delgocitinib?
As a JAK inhibitor, delgocitinib carries potential risks, including an increased risk of serious infections, thrombosis, malignancy, and cardiovascular events [2]. Common side effects reported include nasopharyngitis, dermatitis, and elevated liver enzymes [2].
What is the Regulatory Status of Delgocitinib?
Delgocitinib has received regulatory approval in Japan for the treatment of atopic dermatitis [2]. Regulatory reviews by agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) would be necessary for approval in other major markets [2].
Sources:
[1] https://www.drugpatentwatch.com/medications/delgocitinib/
[2] https://www.torii.co.jp/english/news/pdf/20220121_E.pdf
[3] https://pubchem.ncbi.nlm.nih.gov/compound/Delgocitinib
[4] https://www.drugpatentwatch.com/drug-synthesis-and-manufacturing/
[5] https://www.drugpatentwatch.com/